1 Min Read
FRANKFURT, March 31 (Reuters) - Bayer AG : * Says initiates two phase III trials with Rivaroxaban in medically-ill
patients and children at high risk of blood clots
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.